BACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose
of this multidisciplinary project was to evaluate a possible association of diabetes mellitus …

Purpose We aimed to assess oncological outcomes in colorectal cancer patients with type 2
diabetes mellitus (T2DM) using metformin. Methods Patients with colorectal cancer and …

Evidence from previous studies suggests a protective effect of metformin in patients with
colorectal cancer (CRC). The aim of this study was to examine the associations between …

3589 Background: Insulin resistance and deregulation of the insulin-like growth factor (IGF)
axis is implicated in colonic carcinogenesis. Metformin inhibits hepatic gluconeogenesis and …

Metformin, an antihyperglycemic drug, has been associated with antineoplastic effects and
could potentially improve colorectal cancer prognosis. The association between metformin …

Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer‐
specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate …

Background: Recent studies have suggested an effect of metformin on mortality for patients
with both diabetes and colorectal cancer (CRC). However, the literature is contradictory, with …

Several observational studies have shown that metformin can modify the risk and survival of
colorectal cancer (CRC) in patients with diabetes mellitus, although the magnitude of this …

Background Several studies suggest that metformin has the potential effect of reducing
cancer risk. However, its survival benefit in patients with colorectal cancer (CRC) and …

Objective Current research is controversial about whether metformin can improve the
survival rate of patients with colon cancer. Therefore, we conducted a meta-analysis to …